Apixaban Plasma Concentrations in Patients with Obesity

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2024 Jun 1

PMID 38822847

Authors

Fadiea Al-Aieshy

Mika Skeppholm

Jonas Fyrestam

Fredrik Johansson

Anton Pohanka

Rickard E Malmstrom

Affiliations

Soon will be listed here.

Abstract

Purpose: Routine therapeutic drug monitoring of apixaban is currently not recommended but may however be warranted in some situations and for some patient groups to provide better and safer treatment. Due to limited data on apixaban concentrations in different subpopulations, it is still unclear which group of patients could possibly gain from monitoring. The purpose of this study was to examine apixaban exposure in patients with obesity compared with normal-weight patients.

Methods: Forty patients with obesity (mean BMI 39.4 kg/m) and 40 controls with normal weight (mean BMI 23.4 kg/m), treated with apixaban 5 mg twice daily were included. The patients were matched for age, sex, and renal function. Trough and peak apixaban concentrations were measured with LC‒MS/MS methodology.

Results: The median trough concentrations in patients with obesity (58.7, range 10.7-200.7 ng/ml) were slightly higher than those in patients with normal weight (52.0, range 31.0-150.9 ng/ml) (p < 0.05). Notably, the variability in trough concentration was considerably higher in patients with obesity. Peak concentrations were similar in both groups, with a median of 124.5 ng/ml (range 82.0-277.5) and 113.5 ng/ml (range 75.5-334.6) in patients with obesity and normal weight, respectively.

Conclusion: Apixaban exposure did not vary substantially between obese and normal weight matched controls, implying that general dose adjustments are not required. However, vast interindividual variability was observed in patients with obesity, suggesting that measuring the concentrations could be valuable for specific patients. Further research is needed to identify which specific patients may benefit from this approach.

Citing Articles

The Influence of High Body Mass Index (BMI > 35 kg/m) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation.

Hilu M, Issawy M, Colodner R, Eitam H, Avraham G, Ram K Am J Cardiovasc Drugs. 2024; 25(1):113-123.

PMID: 39424747 PMC: 11775066. DOI: 10.1007/s40256-024-00678-w.

References

Ruff C, Giugliano R, Braunwald E, Morrow D, Murphy S, Kuder J . Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385(9984):2288-95. DOI: 10.1016/S0140-6736(14)61943-7. View

Frost L, Hune L, Vestergaard P . Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005; 118(5):489-95. DOI: 10.1016/j.amjmed.2005.01.031. View

Konstantinides S, Meyer G, Becattini C, Bueno H, Geersing G, Harjola V . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 41(4):543-603. DOI: 10.1093/eurheartj/ehz405. View

Cohen D . Dabigatran: how the drug company withheld important analyses. BMJ. 2014; 349:g4670. DOI: 10.1136/bmj.g4670. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Stein P, Beemath A, Olson R . Obesity as a risk factor in venous thromboembolism. Am J Med. 2005; 118(9):978-80. DOI: 10.1016/j.amjmed.2005.03.012. View

Abed H, Wittert G . Obesity and atrial fibrillation. Obes Rev. 2013; 14(11):929-38. DOI: 10.1111/obr.12056. View

Bjork J, Grubb A, Sterner G, Nyman U . Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. Scand J Clin Lab Invest. 2011; 71(3):232-9. DOI: 10.3109/00365513.2011.557086. View

Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S . Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(6):1308-13. PMC: 4936273. DOI: 10.1111/jth.13323. View

10.

Pineo G, Gallus A, Raskob G, Chen D, Ramirez L, Ramacciotti E . Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013; 11(3):444-51. DOI: 10.1111/jth.12109. View

11.

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2012; 368(8):699-708. DOI: 10.1056/NEJMoa1207541. View

12.

Piran S, Traquair H, Chan N, Bhagirath V, Schulman S . Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018; 2(4):684-688. PMC: 6178753. DOI: 10.1002/rth2.12146. View

13.

Connolly S, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9):806-17. DOI: 10.1056/NEJMoa1007432. View

14.

Reilly P, Lehr T, Haertter S, Connolly S, Yusuf S, Eikelboom J . The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2013; 63(4):321-8. DOI: 10.1016/j.jacc.2013.07.104. View

15.

Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W . Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018; 7(11):728-738. PMC: 6263664. DOI: 10.1002/psp4.12347. View

16.

Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S . Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021; 19(8):1874-1882. DOI: 10.1111/jth.15358. View

17.

Harkness W, Pipitone O, Joss J, Schiedler M, Shagavah S, Moore R . Observed Apixaban Anti-Xa Levels in Obese Patients. Ann Pharmacother. 2022; :10600280221077158. DOI: 10.1177/10600280221077158. View

18.

Lassen M, Raskob G, Gallus A, Pineo G, Chen D, Hornick P . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807-15. DOI: 10.1016/S0140-6736(09)62125-5. View

19.

Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L . Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015; 136(1):148-53. DOI: 10.1016/j.thromres.2015.04.030. View

20.

Martin A, Thomas W, Mahir Z, Crowley M, Dowling T, Breen K . Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. Thromb Haemost. 2020; 121(2):224-233. DOI: 10.1055/s-0040-1715834. View